StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report sent to ...

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, Marketbeat.com ...

Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year End 2024 Financial ... by commercial launch activities in the United States, with products anticipated to be available ...

Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported fourth-quarter net income of $301.3 million. The Silver Spring, Maryland-based company said ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

DURHAM, NC, UNITED STATES, March 5, 2025 /EINPresswire.com/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the ...

"We are delighted that CTD402 has received IND clearance from the US FDA for a phase 1b/2 trial with a simplified dose-finding design, accelerating our clinical development timeline in the United ...

Cambrex Corp., a contract manufacturer of small-molecule therapeutics with a growing facility in High ... Avista’s 330-person workforce will join Cambrex’s 1,700 employees across the United States and ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.